DSE
Basic information
Region (hg38): 6:116254173-116444861
Previous symbols: [ "SART2" ]
Links
Phenotypes
GenCC
Source:
- Ehlers-Danlos syndrome, musculocontractural type 2 (Limited), mode of inheritance: AR
- Ehlers-Danlos syndrome, musculocontractural type 2 (Strong), mode of inheritance: AR
- Ehlers-Danlos syndrome, musculocontractural type 2 (Strong), mode of inheritance: AR
- Ehlers-Danlos syndrome, musculocontractural type 2 (Moderate), mode of inheritance: AR
- Ehlers-Danlos syndrome, musculocontractural type 2 (Strong), mode of inheritance: AR
- Ehlers-Danlos syndrome, musculocontractural type (Supportive), mode of inheritance: AR
Clinical Genomic Database
Source:
Condition | Inheritance | Intervention Categories | Intervention/Rationale | Manifestation Categories | References |
---|---|---|---|---|---|
Ehlers-Danlos syndrome, musculocontractural type 2 | AR | Cardiovascular; Hematologic; Musculoskeletal | Extrapolating from similar types of Ehlers-Danlos syndrome, clinical issues relate to connective tissue fragility may affect multiple organs related to bleeding diatheses (eg, after minor trauma), such that recognition may allow precautions and preventive measures, as well as rapid treatment | Cardiovascular; Craniofacial; Dental; Dermatologic; Gastrointestinal; Hematologic; Musculoskeletal; Neurologic; Ophthalmologic | 23704329 |
ClinVar
This is a list of variants' phenotypes submitted to
- Inborn genetic diseases (1 variants)
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the DSE gene is commonly pathogenic or not.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
Variant type | Pathogenic | Likely pathogenic | VUS | Likely benign | Benign | Sum |
---|---|---|---|---|---|---|
synonymous | 101 | 103 | ||||
missense | 155 | 166 | ||||
nonsense | 5 | |||||
start loss | 0 | |||||
frameshift | 8 | |||||
inframe indel | 1 | |||||
splice donor/acceptor (+/-2bp) | 1 | |||||
splice region | 2 | 2 | ||||
non coding | 27 | 38 | 20 | 87 | ||
Total | 1 | 7 | 190 | 144 | 29 |
Variants in DSE
This is a list of pathogenic ClinVar variants found in the DSE region.
You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.
Position | Type | Phenotype | Significance | ClinVar |
---|---|---|---|---|
6-116278562-C-T | Likely benign (Jun 08, 2018) | |||
6-116278567-G-A | Likely benign (Oct 13, 2022) | |||
6-116278696-T-C | not specified | Benign (Jan 04, 2024) | ||
6-116278715-G-A | Likely benign (Jul 22, 2021) | |||
6-116278733-G-T | not specified • TSPYL1-related disorder | Likely benign (Dec 20, 2023) | ||
6-116278748-A-G | TSPYL1-related disorder | Likely benign (Jul 12, 2019) | ||
6-116278764-A-G | Inborn genetic diseases | Uncertain significance (Apr 09, 2024) | ||
6-116278772-A-G | Likely benign (Sep 03, 2021) | |||
6-116278911-A-G | Sudden infant death-dysgenesis of the testes syndrome | Uncertain significance (-) | ||
6-116278928-T-C | Likely benign (Dec 19, 2022) | |||
6-116278942-C-A | Inborn genetic diseases | Uncertain significance (Oct 04, 2022) | ||
6-116278948-C-T | Inborn genetic diseases | Uncertain significance (Jul 06, 2021) | ||
6-116279003-C-T | Likely benign (Nov 01, 2022) | |||
6-116279076-T-C | Inborn genetic diseases | Uncertain significance (Jan 16, 2024) | ||
6-116279104-TCA-T | Sudden infant death-dysgenesis of the testes syndrome | Pathogenic/Likely pathogenic (Sep 22, 2024) | ||
6-116279184-T-G | Inborn genetic diseases | Uncertain significance (Sep 23, 2023) | ||
6-116279191-C-A | Inborn genetic diseases | Uncertain significance (Nov 04, 2022) | ||
6-116279212-C-T | Inborn genetic diseases | Uncertain significance (Jan 09, 2024) | ||
6-116279230-C-T | Inborn genetic diseases | Uncertain significance (Jul 19, 2022) | ||
6-116279246-C-A | Inborn genetic diseases | Uncertain significance (Apr 08, 2022) | ||
6-116279251-C-A | Uncertain significance (Aug 24, 2022) | |||
6-116279256-ACCT-A | Likely benign (Apr 03, 2023) | |||
6-116279265-T-G | Inborn genetic diseases | Uncertain significance (Jun 11, 2021) | ||
6-116279290-C-T | Benign (Jan 29, 2024) | |||
6-116279302-T-TCAC | Ehlers-Danlos syndrome, musculocontractural type 2 | Benign (Jan 31, 2024) |
GnomAD
Source:
Gene | Type | Bio Type | Transcript | Coding Exons | Length |
---|---|---|---|---|---|
DSE | protein_coding | protein_coding | ENST00000331677 | 5 | 187089 |
pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
---|---|---|---|---|---|---|
0.633 | 0.367 | 125733 | 0 | 15 | 125748 | 0.0000596 |
Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
---|---|---|---|---|---|---|
Missense | 2.03 | 393 | 523 | 0.751 | 0.0000272 | 6327 |
Missense in Polyphen | 111 | 194.65 | 0.57026 | 2379 | ||
Synonymous | 1.08 | 181 | 201 | 0.903 | 0.0000110 | 1853 |
Loss of Function | 4.54 | 8 | 38.3 | 0.209 | 0.00000206 | 422 |
LoF frequencies by population
Ethnicity | Sum of pLOFs | p |
---|---|---|
African & African-American | 0.0000579 | 0.0000579 |
Ashkenazi Jewish | 0.00 | 0.00 |
East Asian | 0.00 | 0.00 |
Finnish | 0.00 | 0.00 |
European (Non-Finnish) | 0.000132 | 0.000105 |
Middle Eastern | 0.00 | 0.00 |
South Asian | 0.0000327 | 0.0000327 |
Other | 0.00 | 0.00 |
dbNSFP
Source:
- Function
- FUNCTION: Converts D-glucuronic acid to L-iduronic acid (IdoUA) residues. {ECO:0000269|PubMed:16505484}.;
- Pathway
- Glycosaminoglycan biosynthesis - chondroitin sulfate / dermatan sulfate - Homo sapiens (human);Metabolism of carbohydrates;Dermatan sulfate biosynthesis;Chondroitin sulfate/dermatan sulfate metabolism;Glycosaminoglycan metabolism;dermatan sulfate biosynthesis (late stages);Proteoglycan biosynthesis;dermatan sulfate biosynthesis;Metabolism
(Consensus)
Recessive Scores
- pRec
- 0.150
Intolerance Scores
- loftool
- 0.761
- rvis_EVS
- -0.35
- rvis_percentile_EVS
- 29.54
Haploinsufficiency Scores
- pHI
- 0.168
- hipred
- Y
- hipred_score
- 0.554
- ghis
- 0.543
Essentials
- essential_gene_CRISPR
- N
- essential_gene_CRISPR2
- N
- essential_gene_gene_trap
- N
- gene_indispensability_pred
- E
- gene_indispensability_score
- 0.841
Gene Damage Prediction
All | Recessive | Dominant | |
---|---|---|---|
Mendelian | Medium | Medium | Medium |
Primary Immunodeficiency | Medium | Medium | Medium |
Cancer | Medium | Medium | Medium |
Mouse Genome Informatics
- Gene name
- Dse
- Phenotype
- growth/size/body region phenotype; integument phenotype (the observable morphological and physiological characteristics of the skin and its associated structures, such as the hair, nails, sweat glands, sebaceous glands and other secretory glands that are manifested through development and lifespan); limbs/digits/tail phenotype; reproductive system phenotype;
Gene ontology
- Biological process
- heparan sulfate proteoglycan biosynthetic process;chondroitin sulfate biosynthetic process;dermatan sulfate biosynthetic process
- Cellular component
- Golgi membrane;nucleoplasm;endoplasmic reticulum;Golgi apparatus;cytosol;integral component of membrane
- Molecular function
- chondroitin-glucuronate 5-epimerase activity